Riluzole likely lacks antidepressant efficacy in ketamine non-responders

J Psychiatr Res. 2014 Nov:58:197-9. doi: 10.1016/j.jpsychires.2014.07.022. Epub 2014 Aug 6.

Authors

Mark J Niciu¹, David A Luckenbaugh², Dawn F Ionescu², Erica M Richards², Jennifer L Vande Voort², Elizabeth D Ballard², Nancy E Brutsche², Maura L Furey², Carlos A Zarate Jr²

Affiliations

¹ National Institutes of Health, National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch (ETPB), 10 Center Dr., Building 10/CRC, Room 7-5545, Bethesda, MD 20892, USA. Electronic address: mark.niciu@nih.gov.
² National Institutes of Health, National Institute of Mental Health, Experimental Therapeutics and Pathophysiology Branch (ETPB), 10 Center Dr., Building 10/CRC, Room 7-5545, Bethesda, MD 20892, USA.

No abstract available

Keywords: Glutamate; Ketamine; Major depressive disorder; Riluzole; Treatment-resistant depression.

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Depressive Disorder, Treatment-Resistant / drug therapy*
Dose-Response Relationship, Drug
Excitatory Amino Acid Antagonists / therapeutic use*
Female
Follow-Up Studies
Humans
Ketamine / therapeutic use*
Male
Middle Aged
Riluzole / therapeutic use*
Treatment Outcome

Substances

Excitatory Amino Acid Antagonists
Ketamine
Riluzole

Grants and funding

Z99 MH999999/Intramural NIH HHS/United States